Back
Recursion Pharmaceuticals, Inc. 10K Form
Sell
38
RXRX
Recursion Pharmaceuticals, Inc.
Last Price:
$4.93
Seasonality Move:
23.28%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RXRX News And Ratings
See the #1 stock for the next 7 days that we like better than RXRX
RXRX Financial Statistics
Sales & Book Value
| Annual Sales: | $58.8M |
|---|---|
| Cash Flow: | $-117.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $2.13 |
| Price / Book: | 2.32 |
Profitability
| EPS (TTM): | -1.81000 |
|---|---|
| Net Income (TTM): | $-715.5M |
| Gross Margin: | $-4.6M |
| Return on Equity: | -80.23% |
| Return on Assets: | -57.87% |
Recursion Pharmaceuticals, Inc. Earnings Forecast
Key Recursion Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 5 years for RXRX is -7.81%.
-
The Selling, General & Administrative Expenses for RXRX have been equal to 302.83% of Gross Profit Margin.
-
The Research & Development expenses have been 503.45% of Revenue.
-
The Net Earning history of RXRX is -788.02% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 0 years.
Recursion Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RXRX |
| Website: | recursion.com |
Debt
| Debt-to-Equity Ratio: | 0.08 |
|---|---|
| Current Ratio: | 4.6 |
| Quick Ratio: | 4.27 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RXRX Technical Analysis vs Fundamental Analysis
Sell
38
Recursion Pharmaceuticals, Inc. (RXRX)
is a Sell
Is Recursion Pharmaceuticals, Inc. a Buy or a Sell?
-
Recursion Pharmaceuticals, Inc. stock is rated a SellThe current Recursion Pharmaceuticals, Inc. [RXRX] share price is $4.92. The Score for RXRX is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.